Giredestrant( GDC-9545 )

Catalog No. M23885 CAS No. 1953133-47-5

Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	210	In Stock
5MG	260	In Stock
10MG	417	In Stock
25MG	785	In Stock
50MG	1251	In Stock
100MG	1962	In Stock
200MG	2673	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Giredestrant
Note

Research use only, not for human use.
Brief Description

Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
Description

Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.
In Vitro

——
In Vivo

——
Synonyms

GDC-9545
Pathway

Endocrinology/Hormones
Target

Estrogen Receptor/ERR
Recptor

ER
Research Area

——
Indication

——

Chemical Information

CAS Number

1953133-47-5
Formula Weight

522.55
Molecular Formula

C27H31F5N4O
Purity

>98% (HPLC)
Solubility

DMSO:100mg/mL (191.37 mM; Need ultrasonic)
SMILES

C[C@H](Cc1c2[nH]c3c1cccc3)N(CC(CO)(F)F)[C@@H]2c(c(F)cc(NC1CN(CCCF)C1)c1)c1F
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.C Metcalfe, et al. Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks